|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In patients with BC, high co-expression of TFCP2L1 and CDK1 was associated with unfavorable clinical characteristics including tumor grade, lymphovascular and muscularis propria invasion, and distant metastasis and was an independent prognostic factor for cancer-specific survival.
|
31709755 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues was significantly associated with disease-free survival (DFS) in PDAC patients (Log rank <i>P</i>=0.00565, <i>P</i>=0.0357, <i>P</i>=0.00104, and <i>P</i>=0.00121, respectively).
|
30765611 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Proteins that contribute most strongly to the proteotype-based classification include INPP4B, CDK1, and ERBB2 and are associated with estrogen receptor (ER) status, tumor grade status, and HER2 status.
|
31315058 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
|
28426773 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review is to recapitulate cyclin B1/CDK1 mediated mitochondrial activities in cell cycle progression and stress response as well as its potential link to reprogram energy metabolism in tumor adaptive resistance.
|
30481564 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate that <sup>177</sup>Lu-lilotomab is particularly efficient in treating tumors with reduced inhibitory CDK1 phosphorylation, such as transformed FL.
|
31836849 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We comprehensively characterized myeloid cells in tumor draining lymph nodes (tdLN) of mice and identified two subsets of conventional type-2 dendritic cells (cDC2) that traffic from tumor to tdLN and present tumor-derived antigens to CD4<sup>+</sup> T<sub>conv</sub>, but then fail to support antitumor CD4<sup>+</sup> T<sub>conv</sub> differentiation.
|
30955881 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of CDK1 was correlated with tumor size and histological grade, and the expression of BUB1 was correlated with the tumor size of PDAC.
|
30898709 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we show that CD103<sup>+</sup> cDC1 and, to a much lesser extent CD11b<sup>+</sup> cDC2, are the only populations expressing TLR3 at the tumor site, and consequently could be potential targets of poly A:U.
|
30949170 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK1 inhibitor RO3306 in combination with sorafenib treatment significantly decreased tumor growth in PDX tumor models.
|
30083256 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cyclin-dependent kinase 1 (CDK1) orchestrates the transition from the G2 phase into mitosis and as cancer cells often display enhanced CDK1 activity, it has been proposed as a tumor specific anti-cancer target.
|
30045664 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CR-LAAO altered the tumor cell expression of DNA repair genes, with two downregulated (XRCC4 and TOPBP1) and three upregulated (ERCC6, RAD52 and CDKN1) genes.
|
29738841 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
|
30365555 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The increase of the tumor-node-metastasis (TNM) staging of osteosarcoma and the high expression of CDC2 are the risk factors affecting the prognosis of osteosarcoma patients (P<0.05), and Cox regression analysis showed that the expression level of CDC2 was a risk factor affecting the prognosis of osteosarcoma patients (P<0.05).
|
29731906 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, CDK1 inhibition imitated the tumor suppressor activity of miR-769 in CRC cells, and restoration of CDK1 expression partially abolished the tumor-suppressing roles of miR-769 in malignant CRC cells.
|
30588014 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We show that transfection with cyclin-dependent kinase 1 (CDK1)-siRNA-loaded nano-Transformers causes up to 95% reduction of relevant mRNA in vitro and greatly inhibits the tumor growth without causing any immunogenic response in vivo.
|
29561622 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, in breast tumors from patients, we found a negative correlation between CDK1 accumulation and βTrCP levels, and a positive correlation with the degree of tumor malignancy.
|
28855742 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Novel interactions of the von Hippel-Lindau (pVHL) tumor suppressor with the CDKN1 family of cell cycle inhibitors.
|
28425505 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that Lebein significantly inhibited LS174 (p53wt), HCT116 (p53wt), and HT29 (p53mut) colon cancer cell viability by inducing cell cycle arrest through the modulation of expression levels of the tumor suppression factor p53, cell cycle regulating proteins cyclin D1, CDK2, CDK4, retinoblastoma (Rb), CDK1, and cyclin-dependent kinase inhibitors p21 and p27.
|
26824338 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hence, exposing RCC cells to amygdalin inhibited cell cycle progression and tumor cell growth by impairing cdk1 and cyclin B expression.
|
26709398 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, primary breast cancers carrying p53 mutations and displaying high YAP activity exhibit higher expression levels of cyclin A, cyclin B, and CDK1 genes when compared to wt-p53 tumors.
|
26691213 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
|
26881434 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance.
|
26141949 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo studies showed that miR-490-3P transfection suppressed tumor development and CDK1, Bcl-xL, MMP2/9 expression while inducing P53 expression.
|
25819031 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we show that clinically relevant CDK1 inhibitors prevent formation of ESC-derived tumors and induce necrosis in established ESC-derived tumors.
|
25733019 |
2015 |